Jounce Therapeutics to Present at Deutsche Bank 43rd Annual Health Care Conference

CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. JNCE, a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that Richard Murray, Ph.D., chief executive officer and president of Jounce, will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 1:30 PM ET in Boston, MA.

A live webcast of the presentation will be available by visiting "Events and Presentations" in the Investors and Media section of Jounce's website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.

About Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce's lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in the Phase 2 portion of the Phase 1/2 ICONIC trial. For more information, please visit www.jouncetx.com.

Investor and Media Contact:

Komal Joshi

Jounce Therapeutics, Inc.

(857) 320-2523

kjoshi@jouncetx.com